New insights into the role of the messenger interleukin 17 (IL-17)
Scientists of the University Medical Center Mainz document a relationship between autoimmune disease and the gut microbiome
(Mainz, 03. March 2021, br) The messenger molecule interleukin 17 (IL-17) does not contribute directly to the development of multiple sclerosis (MS) in the central nervous system (CNS). However, IL-17 does influence the development of experimental autoimmune encephalomyelitis (EAE), the animal model for MS, through the gut microbiome. Current therapies against chronic-inflammatory autoimmune diseases, which target the biological function of IL-17, must therefore be considered with caution due to potential long-term adverse effects on intestinal health. Scientists of the University Medical Center Mainz have now published these important findings in the current issue of the renowned journal “Science Immunology”.
[Translate to englisch:] Regen T, Isaac S, Amorim A, Núñez NG, Hauptmann J, Shanmugavadivu A, Klein M, Sankowski R, Mufazalov IA, Yogev N, Huppert J, Wanke F, Witting M, Grill A, Gálvez EJC, Nikolaev A, Blanfeld M, Prinz I, Schmitt-Kopplin P, Strowig T, Reinhardt C, Prinz M, Bopp T, Becher B, Ubeda C, Waisman A. IL-17 controls central nervous system autoimmunity through the intestinal microbiome. Sci Immunol. 2021 Feb 5;6(56):eaaz6563. doi: 10.1126/sciimmunol.aaz6563. PMID: 33547052.